NCT01611727View on ClinicalTrials.gov

Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

April 30, 2009

Conditions
BRCA1 MutationMetastatic Breast Cancer
Interventions
DRUG

Cisplatin

Cisplatin chemotherapy will be administered as a 75 mg/m2 intravenous (IV) infusion every 3 weeks, for six cycles. Dexamethasone (8mg) will be administered once daily for three days after chemotherapy. Ondansetron (Zofran™) will be used for anti-nausea prophylaxis.

Trial Locations (1)

Unknown

Pomenarian Medical University, Szczecin

All Listed Sponsors
collaborator

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER

lead

Pomeranian Medical University Szczecin

OTHER

NCT01611727 - Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter